FDA Grants Full Approval to Elahere for Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The FDA granted accelerated approval to Elahere in November 2022 for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously administered one to three systemic treatment regimens.

Source link
#FDA #Grants #Full #Approval #Elahere #Patients #Epithelial #Ovarian #Fallopian #Tube #Primary #Peritoneal #Cancer